Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.
Researchers find that surgical decision making is often driven by factors beyond extent of disease.
Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.
The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.
Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.
Partial-breast irradiation failed to meet protocol-defined measures for equivalence.
Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.
CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.
The extension of adjuvant anastrozole to 10 years of treatment showed higher rates of DFS and distant DFS, but did not improve overall survival.